Organon

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organon & Co. - OGN

Retrieved on: 
Monday, February 20, 2023
NYSE, News, Organon & Co., Organon, Private investigator

NEW YORK, Feb. 20, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Organon & Co. (“Organon” or the “Company”) (NYSE: OGN).

Key Points: 
  • NEW YORK, Feb. 20, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Organon & Co. (“Organon” or the “Company”) (NYSE: OGN).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Organon and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.

Eyenuk Welcomes Paul Praino as Chief Commercial Officer

Retrieved on: 
Thursday, February 16, 2023
CCO, DR, Organization, The arts, State University of New York at Plattsburgh, Intersection, Acquisition, Mercy College, Plattsburgh, New York, University, Internal bleeding, Diabetic retinopathy, FDA, Growth, Education, Bachelor of Arts, AI, Innovation system, Medical device, Management, EU, Organon

LOS ANGELES, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Eyenuk , a global artificial intelligence (AI) digital health company, and the leader in real-world applications for AI Eye Screening™ and AI Predictive Biomarkers™, announced the appointment of Paul Praino as the company’s Chief Commercial Officer.

Key Points: 
  • LOS ANGELES, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Eyenuk , a global artificial intelligence (AI) digital health company, and the leader in real-world applications for AI Eye Screening™ and AI Predictive Biomarkers™, announced the appointment of Paul Praino as the company’s Chief Commercial Officer.
  • Praino will oversee the continued development and execution of Eyenuk’s commercial strategy during a time of significant U.S. and international growth for the company.
  • “As more and more healthcare organizations are turning to Eyenuk to expand access to eyesight-saving technology, I am thrilled to welcome Paul as our new CCO to lead our expansion through our next stage of growth," said Kaushal Solanki, CEO and Founder of Eyenuk.
  • “We are confident that his strategic approach and his experience hiring, developing, and motivating the commercial team will drive and accelerate our impact."

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2022

Retrieved on: 
Thursday, February 16, 2023
Medical Devices, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Growth, Heist, Acquisition, Organon, GAAP, Pharmaceutical industry, Cryptocurrency

Adjusted EBITDA margin was 33.8% for the full year 2022 compared with 36.1% for the full year 2021.

Key Points: 
  • Adjusted EBITDA margin was 33.8% for the full year 2022 compared with 36.1% for the full year 2021.
  • Net income from continuing operations for 2022 was $917 million, or $3.59 per diluted share, compared with $1.4 billion, or $5.31 per diluted share in 2021.
  • As of December 31, 2022, cash and cash equivalents were $706 million, and debt was $8.9 billion.
  • These items are uncertain, depend on various factors, and could be material to Organon’s results computed in accordance with GAAP.

Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 16, 2023

Retrieved on: 
Monday, February 6, 2023
Pharmaceutical, Health, Women, Consumer, OGN, ID, EST, Interest, NYSE, Webcast, Security (finance), Organon

Organon (NYSE: OGN), a global women’s healthcare company will release its fourth quarter and full year 2022 financial results on February 16, 2023, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EST.

Key Points: 
  • Organon (NYSE: OGN), a global women’s healthcare company will release its fourth quarter and full year 2022 financial results on February 16, 2023, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EST.
  • Interested parties may access the live call via webcast on the Organon website at https://www.organon.com/investor-relations/events-and-presentations/ .
  • A replay of the webcast will be available approximately two hours after the conclusion of the live event on the company’s website.
  • Institutional investors and analysts interested in participating in the call must register in advance by clicking on this link: https://conferencingportals.com/event/ZGyfDfjk .

Ahead of International Women's Day, Organon Calls for Recognition of the Impacts of Underinvesting in Women's Health

Retrieved on: 
Monday, February 13, 2023
Knowledge, International Women's Day, International Women's Health Coalition, Mother, Woman, Bleeding, Government, Sleep, Menopause, MMR, Abdominal pain, NYSE, Workplace, MENAT, Maternal health, Endometriosis, Health, Research, Mortality, Association of British HealthTech Industries, Associate, Pregnancy, Femtech, OGN, Light, Hypertension, Prevalence, UNICEF, Death, Infection, Hot, Pharmaceutical industry, Dietary supplement, Birth control, Organon

DUBAI, UAE, Feb. 13, 2023 /PRNewswire/ -- For far too long, women's health issues have been underfunded, under researched and underserved. Leading up to International Women's Day on March 8, Organon (NYSE: OGN), a global women's health company, is challenging the healthcare ecosystem – along with academia, investors, policymakers, researchers, and others – to consider the consequences of continuing to treat women's health as an afterthought. For the second consecutive year, the company is also providing its employees, including over 400 employees in the Middle East, North Africa, and Turkey region (MENAT), with paid time off to shine a light and speak out in service of women's health.

Key Points: 
  • Leading up to International Women's Day on March 8, Organon (NYSE: OGN), a global women's health company, is challenging the healthcare ecosystem – along with academia, investors, policymakers, researchers, and others – to consider the consequences of continuing to treat women's health as an afterthought.
  • Mr. Koussa added: "The first step of advancing women's health is listening to women, to understand her needs truly.
  • We continue to work closely with key government stakeholders and various medical societies to educate and empower women".
  • Multiple research and studies across numerous areas of women's health reveal crucial and dangerous gaps that impact nearly all stages of a woman's lifer life.

Ahead of International Women's Day, Organon Calls for Recognition of the Impacts of Underinvesting in Women's Health

Retrieved on: 
Monday, February 13, 2023
Knowledge, International Women's Day, International Women's Health Coalition, Mother, Woman, Bleeding, Government, Sleep, Menopause, MMR, Abdominal pain, NYSE, Workplace, MENAT, Maternal health, Endometriosis, Health, Research, Mortality, Association of British HealthTech Industries, Associate, Pregnancy, Femtech, OGN, Light, Hypertension, Prevalence, UNICEF, Death, Infection, Hot, Pharmaceutical industry, Dietary supplement, Birth control, Organon

DUBAI, UAE, Feb. 13, 2023 /PRNewswire/ -- For far too long, women's health issues have been underfunded, under researched and underserved. Leading up to International Women's Day on March 8, Organon (NYSE: OGN), a global women's health company, is challenging the healthcare ecosystem – along with academia, investors, policymakers, researchers, and others – to consider the consequences of continuing to treat women's health as an afterthought. For the second consecutive year, the company is also providing its employees, including over 400 employees in the Middle East, North Africa, and Turkey region (MENAT), with paid time off to shine a light and speak out in service of women's health.

Key Points: 
  • Leading up to International Women's Day on March 8, Organon (NYSE: OGN), a global women's health company, is challenging the healthcare ecosystem – along with academia, investors, policymakers, researchers, and others – to consider the consequences of continuing to treat women's health as an afterthought.
  • Mr. Koussa added: "The first step of advancing women's health is listening to women, to understand her needs truly.
  • We continue to work closely with key government stakeholders and various medical societies to educate and empower women".
  • Multiple research and studies across numerous areas of women's health reveal crucial and dangerous gaps that impact nearly all stages of a woman's lifer life.

Organon Is Recognized as Both "Top Employers China 2023" And "Best Workplaces™ in Greater China 2022"

Retrieved on: 
Tuesday, January 17, 2023
MATCH International Women's Fund, COVID, Top, Trust, Entrepreneurship, Mental health, Human resources, Certification, Culture, Family, Workplace, OWN, BE, International Women's Day, Knowledge, Senior, Health, Equity, Organization, Agility, Love, Woman, VUCA, Creativity, KEEP, ESG, RISE, Food, Creative industries, Management, Organon, Learning, Greater China

In Organon, we believe bringing the fire of our founders into work is a recipe for success.

Key Points: 
  • In Organon, we believe bringing the fire of our founders into work is a recipe for success.
  • Lia Zuo, Head of Human Resources, Organon China said, "Our people is the key force in our long-term development and success in China.
  • And we have witnessed this in our Top Employers Certification Program this year: exceptional performance from the certified Top Employers 2023.
  • Relying on its efforts, Organon has also been awarded the "Best Workplaces™ in Greater China 2022" titled by the global workplace culture authority Great Place To Work.

Samsung Bioepis Announces Health Canada Approval of Citrate-Free High-Concentration of HUMIRA®¹ Biosimilar (adalimumab; SB5)

Retrieved on: 
Tuesday, January 3, 2023
Partnership, Psoriatic arthritis, Hidradenitis suppurativa, Health Canada, Rheumatoid arthritis, Adalimumab, Organon, Adolescence, SB5, Male, Ankylosing spondylitis, Patient, Uveitis, RA, Safety, Regulatory affairs, Psoriasis, Ulcerative colitis, Generic drug

INCHEON, Korea, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today announced that Health Canada has approved HADLIMA™ (also known as SB5) - a citrate-free, high concentration (40 mg/0.4 ML) formulation of biosimilar referencing HUMIRA® (adalimumab).

Key Points: 
  • INCHEON, Korea, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today announced that Health Canada has approved HADLIMA™ (also known as SB5) - a citrate-free, high concentration (40 mg/0.4 ML) formulation of biosimilar referencing HUMIRA® (adalimumab).
  • “We are pleased to receive Health Canada approval of our high concentration adalimumab biosimilar, marking a key milestone for us now to have both a low and high concentration adalimumab biosimilar approved in Canada,” said Byoungin Jung, Vice President and Regulatory Affairs Team Leader at Samsung Bioepis.
  • The study demonstrated PK equivalence between new SB5 formulation and prior SB5 formulation in healthy subjects.
  • HADLIMA was previously approved by Health Canada as a low-concentration (40mg/0.8mL) formulation in May 2018.

Organon Makes Strategic Investment in Claria Medical to Support Development of Investigational Medical Device for Minimally Invasive Hysterectomy

Retrieved on: 
Thursday, January 5, 2023
Women, Biotechnology, Pharmaceutical, General Health, Health, Medical Devices, Health Technology, Consumer, Food, Research, Knowledge, OGN, Patient, NYSE, Physician, Health, Woman, Step, Pharmaceutical industry, Organon

Organon (NYSE: OGN), a global women’s healthcare company, today announced a strategic investment in Claria Medical, Inc. a privately-held company developing an investigational medical device being studied for use during minimally invasive laparoscopic hysterectomy.

Key Points: 
  • Organon (NYSE: OGN), a global women’s healthcare company, today announced a strategic investment in Claria Medical, Inc. a privately-held company developing an investigational medical device being studied for use during minimally invasive laparoscopic hysterectomy.
  • The agreement also grants Organon the option to acquire Claria Medical.
  • “Collaborations such as our agreement with Claria Medical are integral to our business development approach.
  • Alexey Salamini, Claria Medical’s CEO, commented, “Our team is excited to enter this strategic agreement with Organon, who brings extensive knowledge in women’s health.

ObsEva Announces Dismissal of Moratorium Proceedings

Retrieved on: 
Monday, December 19, 2022
Clinical trial, Investigational New Drug, Drug discovery, Fertilisation, SIX Swiss Exchange, Sale, Pharmaceutical industry, Organon

The Company resolved its over-indebtedness due to the previously announced sale of all its rights to Ebopiprant to XOMA Corporation (XOMA) for an upfront payment of $15 million.

Key Points: 
  • The Company resolved its over-indebtedness due to the previously announced sale of all its rights to Ebopiprant to XOMA Corporation (XOMA) for an upfront payment of $15 million.
  • In July 2021, ObsEva granted a license to Organon for the global development, manufacturing, and commercial rights to Ebopiprant.
  • “The dismissal of moratorium proceedings marks a turning point for ObsEva, as we now look ahead to future development of nolasiban and other strategic options to maximize shareholder value,” said Brian O’Callaghan, CEO of ObsEva.
  • “Having resolved our over-indebtedness and strengthened our financial position with a suite of restructuring initiatives in recent months, we are now focusing our resources on nolasiban.